Following the watershed approval of Iovance’s Lifileucel, TIL therapies are now the major therapeutic avenue for solid tumor treatment.

Returning to Boston is the 6th Annual TIL Therapies Summit, the only meeting uniting the top players in TIL all in one room to unveil:

• The latest clinical data on TIL efficacy for indications beyond melanoma

• Next generation approaches for enhanced persistence and potency

• Manufacturing innovations to scale TILs

• TIL potency assay characterization for swift regulatory approval

• And more!

Reacting to the explosive momentum within this field, the summit has evolved to include more content, in our 2 tracked agenda, pre-clinical and translation and clinical strategy and manufacturing, to cover the A-Z of TIL development.

Event link here.